Trial Profile
Investigation of Pharmacodynamic and Pharmacokinetic Interactions Between 25 mg BI 10773 and 25 mg Hydrochlorothiazide or 5 mg Torasemide Under Steady State Conditions in Patients With Type 2 Diabetes Mellitus in an Open-label, Randomised, Cross-over Trial.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Empagliflozin (Primary) ; Hydrochlorothiazide (Primary) ; Torasemide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 28 Sep 2016 Results assessing pharmacodynamics published in the Clinical Therapeutics.
- 22 Sep 2016 Results published in the Clinical Therapeutics
- 28 Jun 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.